Cure Today23m
FDA Accepts sBLA For Opdivo Plus Yervoy For Some Patients with mCRC
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
pharmaphorum42m
Can Keytruda finally break into early head and neck cancer?
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
Investing Snacks11h
Big Money Moves: Bristol-Myers Squibb Gains Investor Confidence
MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...
Hosted on MSN22h
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...